Agile Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products.
Their product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The lead product candidate, Twirla™, also known as AG200-15, is a once-weekly prescription
contraceptive patch currently in Phase 3 clinical development. Twirla is based on a proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intendedto optimize patch adherence and patient acceptability.
An that's exactly what the buzz is about. Yesterday, the company announced a new patent for it's Skinfusion transdermal delivery service. The stock eventually closed up 35%.
The company went public in June, and has increased almost 100% since then. With a market cap of 192 million and share float of 18 million, the stock might still be a buy. Insiders have bought more than 5 million shares since it's IPO.
"The granting of this patent further strengthens the patent protection of our proprietary Skinfusion® transdermal technology used in our contraceptive patch, Twirla currently in Phase 3 clinical development," said Agile president and CEO Al Altomari. "The issuance of this patent demonstrates our commitment to protecting our intellectual property in our proprietary transdermal technology and is expected to provide protection into 2028."
Their product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The lead product candidate, Twirla™, also known as AG200-15, is a once-weekly prescription
contraceptive patch currently in Phase 3 clinical development. Twirla is based on a proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intendedto optimize patch adherence and patient acceptability.
An that's exactly what the buzz is about. Yesterday, the company announced a new patent for it's Skinfusion transdermal delivery service. The stock eventually closed up 35%.
The company went public in June, and has increased almost 100% since then. With a market cap of 192 million and share float of 18 million, the stock might still be a buy. Insiders have bought more than 5 million shares since it's IPO.
"The granting of this patent further strengthens the patent protection of our proprietary Skinfusion® transdermal technology used in our contraceptive patch, Twirla currently in Phase 3 clinical development," said Agile president and CEO Al Altomari. "The issuance of this patent demonstrates our commitment to protecting our intellectual property in our proprietary transdermal technology and is expected to provide protection into 2028."
RSS Feed